Experimental: GLP1-RA (exenatide) administration ( DrugBank: Exenatide )
2 diseases
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 72 | 下垂体性ADH分泌異常症 | 1 |
| 78 | 下垂体前葉機能低下症 | 1 |
72. 下垂体性ADH分泌異常症
臨床試験数 : 41 / 薬物数 : 27 - (DrugBank : 8) / 標的遺伝子数 : 7 - 標的パスウェイ数 : 10
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04897802 (ClinicalTrials.gov) | September 13, 2021 | 17/5/2021 | Identification and Clinical Relevance of an Oxytocin Deficient State (GLP1 Study) | Identification and Clinical Relevance of an Oxytocin Deficient State: a Randomized, Crossover, Placebo-controlled, Proof-of-concept, Physiopathological Study (GLP1 Study) | Hypopituitarism;Central Diabetes Insipidus;Panhypopituitarism;Psychological Disorder;Social Isolation;Hypothalamic Diseases;Pituitary Diseases;Oxytocin Deficiency | Drug: Experimental: GLP1-RA (exenatide) administration;Drug: Control: Placebo administration | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | Instituto de Salud Carlos III | Recruiting | 18 Years | 65 Years | All | 52 | Phase 4 | Spain |
78. 下垂体前葉機能低下症
臨床試験数 : 492 / 薬物数 : 341 - (DrugBank : 47) / 標的遺伝子数 : 45 - 標的パスウェイ数 : 100
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04897802 (ClinicalTrials.gov) | September 13, 2021 | 17/5/2021 | Identification and Clinical Relevance of an Oxytocin Deficient State (GLP1 Study) | Identification and Clinical Relevance of an Oxytocin Deficient State: a Randomized, Crossover, Placebo-controlled, Proof-of-concept, Physiopathological Study (GLP1 Study) | Hypopituitarism;Central Diabetes Insipidus;Panhypopituitarism;Psychological Disorder;Social Isolation;Hypothalamic Diseases;Pituitary Diseases;Oxytocin Deficiency | Drug: Experimental: GLP1-RA (exenatide) administration;Drug: Control: Placebo administration | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | Instituto de Salud Carlos III | Recruiting | 18 Years | 65 Years | All | 52 | Phase 4 | Spain |